12.41%
-1.04%
-8.37%
-31.80%
-36.57%
17.30%
-21.86%
AI Spotlight on IMNM
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Market Data
| Last Price | 10.51 |
| Change Percentage | 12.41% |
| Open | 9.54 |
| Previous Close | 9.35 |
| Market Cap ( Millions) | 656 |
| Volume | 4883932 |
| Year High | 30.96 |
| Year Low | 8.97 |
| M A 50 | 11.18 |
| M A 200 | 13.32 |
Financial Ratios
| FCF Yield | -14.11% |
| Dividend Yield | 0.00% |
| ROE | -139.72% |
| Debt / Equity | 1.27% |
| Net Debt / EBIDTA | 135.57% |
| Price To Book | 2.94 |
| Price Earnings Ratio | -2.07 |
| Price To FCF | -7.09 |
| Price To sales | 64.76 |
| EV / EBITDA | -4.46 |
News
- Jan -30 - Immunome Can Take The Fight To Competitors With Varegacestat
- Jan -30 - Immunome Announces Pricing of Upsized Public Offering of Common Stock
- Jan -29 - Immunome Announces Proposed Public Offering of Common Stock
- Dec -13 - 3 Small-Cap Stocks With Big Growth Potential
- Nov -27 - Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
- Nov -13 - Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
- Oct -29 - Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
- Oct -08 - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aug -12 - Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
- Jun -27 - Immunome: AL102 And Other Established Protein Targets Could Drive Value
- May -20 - Immunome Announces Completion of Purchase of Assets from Atreca
- May -17 - Immunome Announces Promotion of Max Rosett to Chief Financial Officer
- May -14 - Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
- May -14 - Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
- May -08 - Immunome to Present at 2024 Bank of America Healthcare Conference
- May -02 - Immunome Appoints Kinney Horn as Chief Business Officer
- Apr -26 - Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
- Apr -05 - Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apr -04 - New Strong Sell Stocks for April 4th
- Apr -02 - Immunome: An Oncology Powerhouse In The Making
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biotechnology
Expected Growth : 10.55 %
What the company do ?
Immunome, Inc.'s biotechnology involves developing antibody-based therapies to treat various diseases, leveraging its proprietary antibody discovery platform to identify and isolate therapeutic antibodies.
Why we expect these perspectives ?
Immunome, Inc.'s 10.55% growth in Biotechnology is driven by increasing demand for targeted therapies, advancements in gene editing technologies, and a strong pipeline of novel immunotherapies. Additionally, strategic partnerships and collaborations are fueling innovation and expanding market reach, contributing to the company's rapid growth.
Immunome, Inc. Products
| Product Range | What is it ? |
|---|---|
| IMM-101 | IMM-101 is a therapeutic antibody cocktail designed to treat COVID-19. It is a combination of three antibodies that target the SARS-CoV-2 virus. |
| IMM-201 | IMM-201 is a therapeutic antibody cocktail designed to treat cancer. It targets specific tumor-associated antigens and activates the immune system to fight cancer cells. |
| IMM-301 | IMM-301 is a diagnostic platform that uses proprietary antibody-based technology to detect and diagnose infectious diseases, including COVID-19. |
Immunome, Inc.'s Porter Forces
Threat Of Substitutes
Immunome, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and infectious diseases.
Bargaining Power Of Customers
Immunome, Inc. has a low bargaining power of customers due to the specialized nature of its products and services, which limits the ability of customers to negotiate prices.
Bargaining Power Of Suppliers
Immunome, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services, but the company's dependence on a few key suppliers for critical components.
Threat Of New Entrants
Immunome, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the potential for new companies to enter the market with innovative products and services.
Intensity Of Rivalry
Immunome, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.36% |
| Debt Cost | 3.95% |
| Equity Weight | 98.64% |
| Equity Cost | 13.35% |
| WACC | 13.22% |
| Leverage | 1.38% |
Immunome, Inc. : Quality Control
Immunome, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| PRAX | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive … |
| PTGX | Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Protagonist Therapeutics
A-Score
1-Year Total Return ->
🥉
Praxis Precision Medicines
A-Score
1-Year Total Return ->
4
Poseida Therapeutics
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
